Apexigen (APGN) via Brookline Capital Acq (BCAC) deck
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents.
![](/content/images/size/w1304/2022/03/g336930ex99_2s1g1-1.jpg)